LEADER 04061nam 2200889z- 450 001 9910404076903321 005 20231214133608.0 010 $a3-03928-818-0 035 $a(CKB)4100000011302369 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/50204 035 $a(EXLCZ)994100000011302369 100 $a20202102d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aInfluenza Virus and Vaccination 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (130 p.) 311 $a3-03928-817-2 330 $aThe influenza virus poses a threat to human health and is responsible for global epidemics every year. In addition to seasonal infections, influenza can cause occasional pandemics of great consequence when novel viruses are introduced into humans. Despite the implementation of comprehensive vaccination programs, influenza viruses continue to pose an important and unpredictable global public health threat. They are one of the most significant causes of morbidity and mortality each year and have a significant economic impact. In recent years, research has been conducted to find alternative approaches to influenza vaccine development, including the generation of universal vaccines. Notably, significant progress in the field of influenza infection, transmission, and immunity have contributed to our understanding of influenza biology, and to expanding the technological approaches for the generation of more efficient strategies against influenza infections. Moreover, highly remarkable developments have been made in the implementation of new methodologies to evaluate the efficiency of vaccines and improve them for use on domestic animals such as poultry, horses, dogs or pigs. This enables us to decrease the exposure of humans to potentially pandemic viruses. The articles in this Special Issue will address the importance of influenza to human health and the advances in influenza research that have led to the development of better therapeutics and vaccination strategies. 610 $aheterosubtypic immunity of influenza 610 $amaster donor virus 610 $aimprinting 610 $ahemagglutinin 610 $auniversal vaccines 610 $apandemic 610 $aadaptive immunity 610 $apregnant women 610 $ainnate immunity 610 $aantibodies 610 $aInfluenza vaccine 610 $aARDS 610 $ainfluenza A virus 610 $ahumoral response 610 $ainfluenza vaccine 610 $aoriginal antigenic sin ?OAS? 610 $agerminal centers 610 $aimmunogenicity 610 $alung 610 $aepitopes 610 $aInfluenza virus 610 $asingle nucleotide polymorphisms (SNPs) 610 $ainfluenza virus 610 $aprotein microarray assay 610 $a?universal? influenza vaccine 610 $avaccination 610 $ainfluenza 610 $amultiple dimensional assay (MDA) 610 $ainfection 610 $atissue resident 610 $amemory 610 $avaccines 610 $aCD4 T cell 610 $abroad neutralizing antibody(bnAb) 610 $ahemagglutinin (HA) of influenza virus 610 $aoriginal antigenic sin 610 $aimmune response 610 $amorbidity 610 $aT cell 610 $amPLEX-Flu assay 610 $aInfluenza A virus (IAV) 610 $avirus?host interaction 610 $ahemagglutin stalk 610 $amemory B cells 610 $avaccine safety 610 $aprotection efficacy 610 $alive attenuated influenza vaccine 610 $apediatrics 610 $avaccination rate 700 $aNogales$b Aitor$4auth$01296956 702 $aDeDiego$b Marta L$4auth 906 $aBOOK 912 $a9910404076903321 996 $aInfluenza Virus and Vaccination$93024328 997 $aUNINA